Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BAGSVAERD, DENMARK--(Marketwired - May 17, 2013) - Novo Nordisk today announced the completion of paradigm™ 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. Paradigm™ 2 is a multi-centre, blinded trial evaluating the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in patients with haemophilia B.
Company announcement No 37 / 2013: http://hugin.info/2013/R/1702902/562797.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
[HUG#1702902]
Further information
Media:
Mike Rulis
+45 3079 3573
Email Contact
Ken Inchausti (US)
+1 609 514 8316
Email Contact
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact
Frank Daniel Mersebach
+45 4442 0604
Email Contact
Lars Borup Jacobsen
+45 3075 3479
Email Contact
Jannick Lindegaard (US)
+1 609 786 4575
Email Contact
Help employers find you! Check out all the jobs and post your resume.
